LAVA Therapeutics Statistics
Share Statistics
LAVA Therapeutics has 26.31M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 26.31M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 24.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,696 |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 114.25K, so 0.43% of the outstanding
shares have been sold short.
| Short Interest | 114.25K |
| Short % of Shares Out | 0.43% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 2.25 |
Valuation Ratios
The PE ratio is -1.02 and the forward
PE ratio is -1.22.
LAVA Therapeutics's PEG ratio is
0.03.
| PE Ratio | -1.02 |
| Forward PE | -1.22 |
| PS Ratio | 2.13 |
| Forward PS | 0.5 |
| PB Ratio | 0.92 |
| P/FCF Ratio | -1.3 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for LAVA Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.4,
with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.4 |
| Quick Ratio | 4.4 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | -0.27 |
| Interest Coverage | -57.66 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $352,411.76 |
| Profits Per Employee | $-738,647.06 |
| Employee Count | 34 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 630K |
| Effective Tax Rate | -2.57% |
Stock Price Statistics
The stock price has increased by -60.45% in the
last 52 weeks. The beta is 0.45, so LAVA Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.45 |
| 52-Week Price Change | -60.45% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 51.96 |
| Average Volume (20 Days) | 421,600 |
Income Statement
In the last 12 months, LAVA Therapeutics had revenue of 11.98M
and earned -25.11M
in profits. Earnings per share was -0.94.
| Revenue | 11.98M |
| Gross Profit | 11.52M |
| Operating Income | -29.69M |
| Net Income | -25.11M |
| EBITDA | -23.5M |
| EBIT | -23.97M |
| Earnings Per Share (EPS) | -0.94 |
Full Income StatementBalance Sheet
The company has 35.02M in cash and 5.28M in
debt, giving a net cash position of 29.73M.
| Cash & Cash Equivalents | 35.02M |
| Total Debt | 5.28M |
| Net Cash | 29.73M |
| Retained Earnings | -174.97M |
| Total Assets | 80.83M |
| Working Capital | 61.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -19.54M
and capital expenditures -23K, giving a free cash flow of -19.57M.
| Operating Cash Flow | -19.54M |
| Capital Expenditures | -23K |
| Free Cash Flow | -19.57M |
| FCF Per Share | -0.73 |
Full Cash Flow StatementMargins
Gross margin is 96.1%, with operating and profit margins of -247.81% and -209.6%.
| Gross Margin | 96.1% |
| Operating Margin | -247.81% |
| Pretax Margin | -204.34% |
| Profit Margin | -209.6% |
| EBITDA Margin | -196.14% |
| EBIT Margin | -247.81% |
| FCF Margin | -163.3% |
